Archemix Corp.
- Country
- 🇺🇸United States
- Ownership
- Private, Subsidiary
- Established
- 2000-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.archemix.com
Clinical Trials
13
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
- Conditions
- Intracranial EmbolismCerebral ThromboembolismCarotid Stenosis
- Interventions
- Drug: ARC1779 InjectionDrug: Placebo (normal saline)
- First Posted Date
- 2008-08-27
- Last Posted Date
- 2010-02-10
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 100
- Registration Number
- NCT00742612
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Eddy Scurlock Stroke Center - Methodist Hospital, Houston, Texas, United States
🇬🇧Addenbrooke's Hospital, Department of Vascular Surgery, Cambridge, United Kingdom
Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy
- Conditions
- Thrombotic MicroangiopathyThrombotic Thrombocytopenic Purpura
- Interventions
- Drug: ARC 1779 PlaceboDrug: ARC1779 Injection
- First Posted Date
- 2008-08-01
- Last Posted Date
- 2009-11-26
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 100
- Registration Number
- NCT00726544
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸Indiana University Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸Washington University, St. Louis, Missouri, United States
A Study of the Pharmacokinetics, Pharmacodynamics, and Safety of ARC1779 Injection in Patients With Von Willebrand Disease Type 2B
- First Posted Date
- 2008-06-10
- Last Posted Date
- 2009-08-21
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 2
- Registration Number
- NCT00694785
ARC1779 Injection in Patients With Von Willebrand Factor-Related Platelet Function Disorders
- Conditions
- Purpura, Thrombotic ThrombocytopenicVon Willebrand Disease Type-2b
- Interventions
- First Posted Date
- 2008-03-10
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 28
- Registration Number
- NCT00632242
- Locations
- 🇦🇹
Archemix Investigational Site, Vienna, Austria
Study of ARC1779 in Patients With Acute Myocardial Infarction Undergoing PCI
- Conditions
- Acute Myocardial Infarction
- First Posted Date
- 2007-07-26
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Archemix Corp.
- Target Recruit Count
- 300
- Registration Number
- NCT00507338
- Locations
- 🇷🇺
Archemix Investigational Site, St. Petersburg, Russia, Russian Federation
- Prev
- 1
- 2
- Next